Pancreatic neuroendocrine tumours in patients with von Hippel-Lindau disease

Endokrynol Pol. 2020;71(3):256-259. doi: 10.5603/EP.a2020.0027.

Abstract

Von Hippel-Lindau disease is a highly penetrant autosomal genetic disorder caused by a germline mutation in the tumour suppressor gene, manifesting with the formation of various tumours, including neuroendocrine tumours of the pancreas. The incidence of the latter is not very high, varying from 5% to 18%. To compare, haemangioblastomas and clear cell renal carcinoma are present in 70% of von Hippel-Lindau patients and are considered the main prognostic factors, with renal cancer being the most common cause of death. However, pancreatic neuroendocrine tumours should not be neglected, considering their malignant potential (different to sporadic cases), natural history, and treatment protocol. This paper aims to review the literature on the epidemiology, natural history, treatment, and surveillance of individuals affected by pancreatic neuroendocrine tumours in von Hippel-Lindau disease.

Keywords: pancreatic neuroendocrine tumours; von Hippel-Lindau disease.

Publication types

  • Review

MeSH terms

  • Female
  • Humans
  • Male
  • Neuroendocrine Tumors / complications*
  • Neuroendocrine Tumors / genetics
  • Neuroendocrine Tumors / therapy*
  • Pancreatic Neoplasms / complications*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / therapy*
  • Prognosis
  • von Hippel-Lindau Disease / genetics
  • von Hippel-Lindau Disease / pathology
  • von Hippel-Lindau Disease / therapy*